Walleye Trading’s ProQR Therapeutics PRQR Stock Holding History

Walleye Trading’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-944	Closed	-$18K	–	5169
2018 Q3	$18K	Buy	+944	New	+$10K	﹤0.01%	4874
2016 Q2	–	Sell	-3,000	Closed	-$15K	–	5652
2016 Q1	$15K	Buy	+3,000	New	+$15.3K	﹤0.01%	4581
2015 Q4	–	Sell	-1,900	Closed	-$28K	–	5602
2015 Q3	$28K	Buy	+1,900	New	+$31.8K	﹤0.01%	3888

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Walleye Trading's PRQR Position: Q4 2018 in Review

Walleye Trading sold out of ProQR Therapeutics (PRQR) in Q4 2018, closing a stake of 944 shares — an estimated $18K sold.

Walleye Trading first reported a position in PRQR in Q3 2015 and held it in 3 quarters. The position peaked at $28K in Q3 2015. 57 funds tracked by Wall St. Rank hold PRQR as of Q4 2018.

Walleye Trading reported no remaining ProQR Therapeutics position as of Q4 2018 after selling out during the quarter.
Walleye Trading sold 944 ProQR Therapeutics shares in Q4 2018, an estimated $18K.
Walleye Trading first reported a position in ProQR Therapeutics in Q3 2015 and held it in 3 quarters.
Walleye Trading's ProQR Therapeutics position peaked at $28K in Q3 2015.
57 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2018.

Based on Walleye Trading's 13F filing for Q4 2018, filed 14 Feb 2019.